1. 1) Hardman WE, Moyer MP, Cameron IL. Efficacy of treatment of colon, lung and breast human carcinoma xenografts with: doxorubicin, cisplatin, irinotecan or topotecan. Anticancer Res., 19 (3B), 2269–2274 (1999).
2. 2) Ridwelski K, Gebauer T, Fahlke J, Kroning H, Kettner E, Meyer F, Eichelmann K, Lippert H. Combination chemotherapy with docetaxel and cisplatin for locally advanced and metastatic gastric cancer. Ann. Oncol., 12, 47–51 (2001).
3. 3) Gillet JP, Gottesman MM. Mechanisms of multidrug resistance in cancer. Methods Mol. Biol., 596, 47–76 (2010).
4. 4) Torchilin VP. Drug targeting. Eur. J. Pharm. Sci., 11 (Suppl. 2), S81–S91 (2000).
5. 5) Hind D, Tappenden P, Tumur I, Eggington S, Sutcliffe P, Ryan A. The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation. Health Technol. Assess., 12, iii–ix, xi–162 (2008).